The bidding window for the Sampat Aluminium SME IPO was open from September 17, 2025, to September 19, 2025. The basis of allotment will be finalised today, September 22, 2025. Here’s how you can check the IPO allotment status on the BSE and registrar’s website.
Sampat Aluminium IPO is a book-building issue of ₹30.53 crores, consisting entirely of a fresh issue of 0.25 crore equity shares. The price band is set at ₹114 to ₹120 per share. The tentative listing on BSE SME is September 24, 2025.
Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. is the book-running lead manager, and Cameo Corporate Services Limited is the registrar for the issue.
The net proceeds from the fresh issue will be used to fund capital expenditure towards:
(September 19, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
87.02 |
Non-Institutional Investors |
201.42 |
Individual Investors (IND category bidding for 2 Lots) |
161.90 |
Total |
153.80 |
As of 22 September 2025, Sampat Aluminium IPO GMP stood at ₹13. The estimated listing price is ₹133, i.e., a gain of 10.83% per share.
Source: InvestorGain Report dated 22 September 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Sampat Aluminium manufactures cast and hot-rolled aluminium long products, including aluminium wires in sizes of 5.5 mm and 6.5 mm and aluminium rods in sizes of 7.5 mm, 9.5 mm, 12.5 mm, 16 mm & 20 mm. The procedure is done through the procurement of aluminium ingots, rods, and wires and also by recycling aluminium scrap.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.